OVERLAND PARK, Kan., Oct. 16, 2016 -- Pets owners can participate in a new study to advance arthritis treatment in dogs. The 12-week study includes blood work, X-rays and a supply of a joint supplement after study completion at no additional cost to participating dog owners, reports Nall Hills Animal Hospital. Local dog owners with canines with arthritis are invited to participate to study the effectiveness of a specific joint supplement.
Like humans, dogs can experience significant pain and reduced mobility with the onset of arthritis. Studies such as this one, presented by the veterinarian team at Nall Hills Animal Hospital, provides additional understanding of potential treatment options. Dogs at any age, but especially senior pets, may benefit from this study.
Dog owners interested in participating in the study should be aware that candidates for the study must not be taking any corticosteroids or non-steroidal anti-inflammatories (NSAIDs); owners must have internet access and be able to visit the hospital weekly for up to 12 weeks. Participating dog owners can expect blood work and X-rays at the time of enrollment to measure the effectiveness of care, and a supply of a joint supplement after the end of the study.
Arthritis can occur in any of a dog’s joints. Osteoarthritis is a common type of arthritis and can occur due to aging, injury, overuse or an unstable joint. Some forms of arthritis, such as septic arthritis, are a result of a bacterial or fungal infection. There are a variety of arthritis treatments available, including supplements, medication, cartilage protective agents, acupuncture, pain medication and steroids to help pet owners support the needs of their dogs with arthritis.
“Area dog owners are invited to participate in our 12-week study on a joint supplement to treat arthritis in dogs,” said Dr. John Teeter, DVM. “Our purpose is to test the effectiveness of a joint supplement and we appreciate the participation of area dog owners and their pets. Your help can allow us to learn more about how to effectively and safely treat arthritis in your beloved pet and in other dogs with arthritic symptoms.”
Dr. John Teeter, Dr. Robin Goodyear and Dr. Melissa Minor of Nall Hills Animal Hospital serve pets and their owners in and around Overland Park. Pet owners can expect quality veterinary care for prevention and treatment. Their veterinarian team stresses proper home care to ensure a healthy life for pets and partners with pet owners to develop individual care plans. Veterinary services include pet exams, pet dental, laser surgery, end-of-life decisions for pets, grooming, flea and tick treatment, pet digital radiography and boarding.
Call (913) 808-3181 to learn more about participating in the 12-week study for dogs with arthritis or visit http://nallhillsanimalhospital.com/ for details.
Nall Hills Animal Hospital, (913) 808-3181


Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Italy Fines Apple €98.6 Million Over App Store Dominance
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



